Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	665.13	661.82	607.52	667.24	579.78	520.4
Revenue Growth (YoY)	5.55%	8.94%	-8.95%	15.09%	11.41%	32.50%
Cost of Revenue	76.27	77.91	83.78	87.22	75.06	52.46
Gross Profit	588.85	583.91	523.74	580.02	504.71	467.94
Selling, General & Admin	352.26	335.78	336.36	377.22	304.76	200.68
Research & Development	106.73	108.8	91.59	74.55	90.47	75.96
Operating Expenses	537.32	522.56	510.34	534.4	425.22	292.34
Operating Income	51.54	61.36	13.4	45.61	79.5	175.6
Interest Expense	-	-	-2.42	-7.07	-23.42	-23.75
Interest & Investment Income	1.82	-	-	-	10.22	14.35
Other Non Operating Income (Expenses)	16.2	16.2	10.45	21.68	-	-
EBT Excluding Unusual Items	69.55	77.55	21.44	60.22	66.3	166.2
Gain (Loss) on Sale of Investments	0.01	0.01	-	0.01	0.35	4.35
Asset Writedown	-	-	-20.19	-	-	-
Other Unusual Items	-7	6.11	1.52	0.51	6.53	-1.9
Pretax Income	82.16	97.87	2.77	60.74	73.18	168.65
Income Tax Expense	17.67	24.01	1.45	0.03	19.75	41.7
Net Income	64.5	73.87	1.32	60.71	53.42	126.95
Net Income to Common	64.5	73.87	1.32	60.71	53.42	126.95
Net Income Growth	1131.09%	5512.84%	-97.83%	13.64%	-57.92%	12.29%
Shares Outstanding (Basic)	56	55	55	54	53	53
Shares Outstanding (Diluted)	56	56	56	62	54	54
Shares Change (YoY)	3.11%	0.81%	-10.01%	13.47%	1.24%	-0.24%
EPS (Basic)	1.16	1.34	0.02	1.13	1.01	2.41
EPS (Diluted)	1.14	1.32	0.02	1.04	0.98	2.36
EPS Growth	1411.53%	6500.00%	-98.08%	6.32%	-58.48%	12.38%
Free Cash Flow	185.87	171.23	110.53	116.41	125.08	134.71
Free Cash Flow Per Share	3.29	3.06	1.99	1.89	2.30	2.51
Gross Margin	88.53%	88.23%	86.21%	86.93%	87.05%	89.92%
Operating Margin	7.75%	9.27%	2.21%	6.84%	13.71%	33.74%
Profit Margin	9.70%	11.16%	0.22%	9.10%	9.21%	24.39%
Free Cash Flow Margin	27.94%	25.87%	18.19%	17.45%	21.57%	25.89%
EBITDA	132.22	141.77	98.26	131.16	112.09	193.74
EBITDA Margin	19.88%	21.42%	16.17%	19.66%	19.33%	37.23%
D&A For EBITDA	80.69	80.41	84.86	85.54	32.6	18.14
EBIT	51.54	61.36	13.4	45.61	79.5	175.6
EBIT Margin	7.75%	9.27%	2.21%	6.84%	13.71%	33.74%
Effective Tax Rate	21.50%	24.53%	52.47%	0.05%	26.99%	24.73%
Revenue as Reported	665.13	661.82	607.52	667.24	579.78	520.4

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q